Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088130 | 0.91 | HTT (0.57) | ADORA2AADORA1CYP3A4HTTALDH1A1 | |
| SCHEMBL2814529 | 0.87 | ADORA2A (0.65) | ADORA2AADORA1CYP3A4HTT | |
| SCHEMBL3086906 | 0.87 | ADORA2A (0.57) | ADORA2AADORA1CYP3A4HTTALDH1A1 | |
| SCHEMBL3087723 | 0.84 | ALDH1A1 (0.59) | ADORA2AADORA1CYP3A4HTTALDH1A1 | |
| SCHEMBL3085450 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4ALDH1A1 | |
| SCHEMBL3077398 | 0.81 | ADORA2A (0.64) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5016104 | 0.78 | ADORA2A (0.59) | ADORA2AADORA1CYP3A4 | |
| SCHEMBL5017619 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1CYP3A4 | |
| SCHEMBL5022290 | 0.77 | ADORA2A (0.81) | ADORA2AADORA1CYP3A4 | |
| SCHEMBL1936057 | 0.76 | HTT (0.86) | CYP3A4HTTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ADORA2A 3/4885ADORA1 2/4885CYP3A4 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.